AGC Biologics has been tapped to manufacture Provention Bio’s long-awaited Type 1 juvenile diabetes treatment that had been in development for more than 36 years before getting FDA approval late last year.
AGC will produce Tzield (teplizumab-mzwv) at its Seattle protein biologics facility, the CDMO said in a Jan. 24 press release. The company was heavily involved with the advancement of the treatment through early manufacture and validation batches, and U.S. regulatory approval.
